Remegen -H (9995.HK) traded up 2.62 % during a 24 hours period ending at 07:31 PM Central Europe on Monday 26th. One Remegen -H stock can currently be bought for about HKD 64.5 on popular exchanges. Current supply of Remegen -H stocks is 208.6 mn. Remegen -H has a current market capitalization of HKD 38.4 bn and approximately HKD 129.4 mn worth of Remegen -H was traded on exchanges in the last 24 hours. Since last month end, Remegen -H has traded -11.45 % down. Simple moving average of last 200 days is at HKD 84.08. The highest price of past 52 weeks was recorded at HKD 123.1 on 04/20/2026. 52 weeks low was at HKD 60 on 10/23/2026.
Here is how related stocks have performed in the past 24 hours:
Wanxiang Qianchao (000559.SZ) traded flat 0 % and now trades at CNY 12.71. Wanxiang Qianchao has a market capitalisation of CNY 38.5 bn. Current price/earnings ratio for Wanxiang Qianchao is 38.69. On October 26, the Shanghai Composite finished in modest gain, while the ChiNext and Shenzhen indices declined. Trading volume fell relative to the prior day, and more than 3,100 stocks ended in the red. The day’s most active theme remained robotics, with several companies posting consecutive price limits and a few new listings. Data‑asset names also gained momentum, with several shares reaching their daily upper limits. Consumer staples such as alcohol, food and dairy products posted notable upside, and the energy sector, led by a major national oil company, reached a new high since 2008. In contrast, hardware and semiconductor related shares suffered weaker moves, with several experiencing multiple days of decline. Net capital inflows were strongest into a handful of technology and industrial stocks, while the electronics and semiconductor segments saw a net outflow of funds. The market sentiment remained cautious, reflecting the need for a stable foundation before any broader rally can materialise.
Suzhou Maxwell Technologie (300751.SZ) traded flat 0 % and now trades at CNY 134.18. Current market capitalisation for Suzhou Maxwell Technologie is CNY 38.5 bn. Current price/earnings ratio for Suzhou Maxwell Technologie is 66.23.
Hunan Yuneng New Energy Ba (301358.SZ) traded flat 0 % and now trades at CNY 45.38. Current market capitalisation for Hunan Yuneng New Energy Ba is CNY 38.8 bn. Hunan Yuneng New Energy BA reported that its recent financial disclosures reflected a modest decline in revenue and net profit compared to the same period last year. The company’s earnings, driven by its core product lines, have shown a downward trend, particularly in its domestic sales segment. While the firm has made strategic acquisitions to diversify into new materials, these initiatives have yet to generate substantial revenue impact. The company highlighted that its newly integrated assets are still in early stages, with limited contribution to overall profitability. Management emphasized cautious outlooks for future performance, noting that any underperformance of the newly acquired businesses could pose a risk to the company’s valuation. The update also noted that the company’s upcoming share unlock event may influence the market dynamics.
Orient Securities (3958.HK) traded up 2.55 % and now trades at HKD 5.42. Orient Securities has a market capitalisation of HKD 46.1 bn. Current price/earnings ratio for Orient Securities is 7.14. Orient Securities Co. Ltd. has reported solid performance in its recent financial statements, with revenues and net profit rising across the first three quarters of the year. The company’s earnings resilience is highlighted by steady gains in brokerage and credit activities, while investment income has moderated due to market volatility. Dividend payouts have increased, reflecting a growing emphasis on shareholder returns, and the firm’s dividend yield has approached levels typical of established dividend-paying sectors. Analysts note that Orient Securities’ valuation remains attractive, with a price‑to‑earnings ratio near a decade‑low, and the company’s strong earnings and dividend policy support expectations of a gradual valuation recovery. The outlook remains positive as the firm continues to navigate a challenging market environment with a focus on robust profitability and shareholder value.
Giant Network (002558.SZ) traded flat 0 % and now trades at CNY 20.92. Current market capitalisation for Giant Network is CNY 38.6 bn. Giant Network has a current price to earnings ratio of 12.33.
About Remegen -H
RemeGen Co., Ltd., a biotechnology company based in Yantai, China, specializes in developing therapeutic antibody drugs. These include antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and double antibodies. RemeGen provides solutions for autimmune diseases, tumor diseases, and ophthalmic diseases. You can find more information about their operations on their website, www.remegen.com , and they are listed on the Hong Kong Stock Exchange.